Abstract #2897

pH-weighted amine CEST-EPI as a fast clinical imaging biomarker for early bevacizumab treatment response in recurrent GBM

Jingwen Yao^1,2,3, Caleb Tan⁴, Ararat Chakhoyan^1,3, Catalina Raymond^1,3, Noriko Salamon³, Linda Liau^5,6, Phioanh Nghiemphu⁷, Albert Lai^6,7, Whitney Pope³, Timothy Cloughesy⁷, and Benjamin Ellingson^1,2,3,6,8,9

¹Brain Tumor Imaging Laboratory (BTIL), Center of Computer Vision and Imaging Biomarker, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ²Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, United States, ³Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁴Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, United States, ⁵Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁶UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁷Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁸Physics and Biology in Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁹Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

In the current study we used amine CEST-EPI, a pH-sensitive fast chemical exchange saturation transfer (CEST) technique, as a potential non-invasive imaging biomarker for treatment response in recurrent GBM patients treated with bevacizumab. Results suggest a significantly lower MTR_asym at 3.0ppm in recurrent GBM tumors after bevacizumab treatment may be associated with better patient outcome (PFS), indicating that pH-weighted amine CEST MRI could serve as a potential non-invasive imaging biomarker for treatment response evaluation. The colocalization of recurrence tumor site and high MTR_asym contrast post-treatment further suggest pH-weighted amine CEST may provide valuable information for early detection of tumor progression.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.